Heterocyclic Monomer Patents (Class 424/78.3)
-
Patent number: 8597633Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.Type: GrantFiled: February 22, 2013Date of Patent: December 3, 2013Assignee: Serina Therapeutics, inc.Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
-
Patent number: 8586681Abstract: The invention provides methods for making copolymers and multi-arm block copolymers useful as drug delivery vehicles. The multi-arm block copolymers comprise a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.Type: GrantFiled: November 19, 2012Date of Patent: November 19, 2013Assignee: Nektar TherapeuticsInventor: Xuan Zhao
-
Patent number: 8580244Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: February 15, 2013Date of Patent: November 12, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Patent number: 8580242Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: January 11, 2013Date of Patent: November 12, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kat T. Khin
-
Patent number: 8580243Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: February 15, 2013Date of Patent: November 12, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Patent number: 8574557Abstract: Present invention provides a composition for a cosmetic comprising a fluorine-containing silicone polymer having a three-dimensional, cross-linked structure, prepared by addition polymerizing the following (A), (B) and (C) and containing 10 to 30 mass % of the fluorine atoms, relative to a total mass of (A) to (C), (A) a vinyl group-containing organopolysiloxane represented by the following formula (1): (B) an organohydrogenpolysiloxane represented by the following formula (2): and (C) an organopolysiloxane having a reactive group on one end alone and represented by the following formula (3), and further comprising (D) a low viscosity silicone oil with a dynamic viscosity of 50 mm2/s or less at 25 degrees C.Type: GrantFiled: March 3, 2011Date of Patent: November 5, 2013Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Chihiro Hayakawa, Hiromasa Yamaguchi
-
Publication number: 20130280203Abstract: A preparation method of a high-stable non-ionic N-vinyl butyrolactam iodine solution is provided, wherein high-stable non-ionic N-vinyl butyrolactam iodine is dissolved in water, then citric acid, at least one iodine ion stabilizing agent, at least one non-ionic surfactant and at least one emulsifier are added, then the pH is adjusted to 5 with at least one pH adjusting agent, so as to prepare the high-stable non-ionic N-vinyl butyrolactam iodine solution, the high-stable non-ionic N-vinyl butyrolactam iodine is formed by complexing PVP-K30, iodine and at least one grinding aid at a temperature of 60° C.-90° C., the high-stable non-ionic N-vinyl butyrolactam iodine solution prepared by the above mentioned method is also provided, the stability of the high-stable non-ionic N-vinyl butyrolactam iodine solution of the present invention is high.Type: ApplicationFiled: August 18, 2011Publication date: October 24, 2013Inventors: Yu Wang, Zhan Chen
-
Publication number: 20130243719Abstract: The present invention relates to novel conjugates of active principles grafted to a polymer, to the nanoparticles comprising them, to their preparation and to their polymeric intermediates.Type: ApplicationFiled: November 18, 2011Publication date: September 19, 2013Applicants: SANOFI, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Abderrhamane Amgoune, Didier Bazile, Fethi Bensaid, Didier Bourissou, Eric Didier, Stephanie Greco, Harivardhan Reddy Lakkireddy, Serge Sable, Michel Veillard
-
Patent number: 8535656Abstract: Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided.Type: GrantFiled: March 9, 2012Date of Patent: September 17, 2013Assignee: Board of Regents of the University of NebraskaInventors: Alexander V. Kabanov, Xiang Yi, Sarguel V. Vinogradov, William A. Banks
-
Patent number: 8524214Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.Type: GrantFiled: May 27, 2010Date of Patent: September 3, 2013Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Gui Liu, Laura C. Akullian, John J. Kane, Cheri A. Stevenson, Charles E. Hammond, Russell C. Petter, John H. Van Duzer, Timothy B. Lowinger
-
Patent number: 8518388Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: January 11, 2013Date of Patent: August 27, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Patent number: 8501899Abstract: The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.Type: GrantFiled: January 23, 2012Date of Patent: August 6, 2013Assignee: Serina Therapeutics, Inc.Inventors: Kunsang Yoon, J. Milton Harris, Michael David Bentley, Zhihao Fang, Tacey Viegas
-
Patent number: 8501199Abstract: The present invention concerns novel synthetic blocking reagents for the reduction of non-specific bindings in solid phase assays that rely on biological and specific recognition, e.g., in enzyme-linked immunosorbent assays (ELISAs). The invention provides the use of compounds as blocking reagents as well as kits comprising these compounds. The compounds comprise one or more poly(ethylene glycol) moieties, one or more alkyl- or aminoalkyl groups and another unit bridging the aforementioned groups, wherein the compound comprises at least one amino group.Type: GrantFiled: June 10, 2010Date of Patent: August 6, 2013Assignee: Forschungszentrum BorstelInventors: Naho Fujimoto, Niels Röckendorf, Steffen Bade, Katrin Ramaker, Andreas Frey
-
Publication number: 20130189340Abstract: A donor capable of controlled release of nitric monoxide and a prosthetic implant whose surface is coated with this donor are disclosed. The donor comprises a main chain of an organic polymer and a side chain that is covalently linked to the main chain and has a diazeniumdiolate functional group. The donor for controlled release of nitric monoxide exists in a fluid state such as liquid at room temperature and undergoes a sol-to-gel phase transition at a physiological pH as the temperature increases above the critical temperature. The critical temperature of the phase transition is in the range of 25 to 35° C., and the gel is a hydrogel without chemical cross-links.Type: ApplicationFiled: October 4, 2011Publication date: July 25, 2013Inventors: Won Jong Kim, Yanggy Lee, Kwideok Park, Jihoon Kim, Dong Keun Han
-
Publication number: 20130183262Abstract: A compound having the formula: wherein n, y, R1 and R2 are defined herein, and others, methods of making of and using, and compositions made thereby which have an antimicrobial resistance effect are described.Type: ApplicationFiled: October 31, 2012Publication date: July 18, 2013Inventors: Kenneth J. Wynne, Souvik Chakrabarty, Wei Zhang, Asima Chakravorty, Olufemi O. Oyesanya
-
Publication number: 20130177521Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.Type: ApplicationFiled: February 22, 2013Publication date: July 11, 2013Applicant: Serina Therapeutics, Inc.Inventor: Serina Therapeutics, Inc.
-
Publication number: 20130172405Abstract: The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).Type: ApplicationFiled: December 21, 2012Publication date: July 4, 2013Applicant: PROTIVA BIOTHERAPEUTICS INC.Inventor: PROTIVA BIOTHERAPEUTICS INC.
-
Patent number: 8475781Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: August 10, 2012Date of Patent: July 2, 2013Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark Davis, Kay T. Khin
-
Publication number: 20130156721Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: CERULEAN PHARMA INC.Inventor: CERULEAN PHARMA INC.
-
Publication number: 20130149351Abstract: The present invention provides for scaffolds for growing RPE cells, comprising two or more biodegradable polymers. The present invention also provides for methods for creating a scaffold for growing RPE cells. Additionally, the present invention provides for RGD peptide linked polymer scaffolds for supporting the growth of RPE cells. The present invention provides methods of culturing RPE cells using the scaffolds produced herein. The present invention also provides methods of treating vision loss through the administration of RPE cell attached RGD peptide linked polymer scaffolds produced herein. The present invention further provides kits for treating vision loss.Type: ApplicationFiled: December 7, 2012Publication date: June 13, 2013Applicants: UNIVERSITY OF SOUTHERN CALIFORNIA, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: California Institute of Technology, University of Southern California
-
Publication number: 20130142733Abstract: In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: January 4, 2011Publication date: June 6, 2013Applicant: Vanderbilt UniversityInventors: Eva M. Harth, David J. Calkins, Alice E. Van Der Ende
-
Publication number: 20130136714Abstract: PEO-PPO-PEO polymers and vinyl monomers are used to prepare several block copolymers via consecutive atom transfer radical polymerization (ATRP). The block copolymers provide good delivery characteristics and can be used as a gene/drug delivery carrier for therapy and diagnosis.Type: ApplicationFiled: August 10, 2012Publication date: May 30, 2013Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Li-Fang Wang, Shih-Jer Huang, Zhi-Rong Hsu
-
Publication number: 20130129662Abstract: The invention provides a therapeutic composition comprising an aqueous buffer, and a therapeutic agent that proves the functioning of a diseased heart by decreasing left ventricular end-diastolic pressure and simultaneously increasing left ventricular ejection without affecting the blood pressure or heart rate.Type: ApplicationFiled: December 13, 2012Publication date: May 23, 2013Applicant: Phrixus Pharmaceuticals, Inc.Inventor: Phrixus Pharmaceuticals, Inc.
-
Patent number: 8440176Abstract: The invention relates to graftable polymers comprising biologically active agents and the use of such polymers in the manufacture of shaped articles, such as implantable medical devices and catheters. The graftable polymers are covalently grafted to a surface via one or more grafting moieties incorporated into the pharmaceutically-active graftable polymer. The coated articles of the invention can further comprise tie-coats, and the ratio of polymer:tie coat can be used to adjust the rate of drug elution.Type: GrantFiled: April 24, 2009Date of Patent: May 14, 2013Assignee: Interface Biologics, Inc.Inventors: Frank Laronde, Fan Gu
-
Patent number: 8436119Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 10, 2013Date of Patent: May 7, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Patent number: 8431113Abstract: The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl-2?-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimising the delivery characteristics of the active agent.Type: GrantFiled: September 23, 2011Date of Patent: April 30, 2013Assignee: Biocompatibles UK LimitedInventor: Andrew Lennard Lewis
-
Publication number: 20130101632Abstract: Methods and formulations for improving therapeutic potential of mithramycin (MTM) or MTM analogues are disclosed. For example, in certain aspects, methods for preparing a composition containing MTM or an MTM analogue nanoparticulate formulation and uses thereof are described. Furthermore, methods for delivering MTM or MTM analogues are disclosed.Type: ApplicationFiled: September 20, 2012Publication date: April 25, 2013Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventor: University of Kentucky Research Foundation
-
Patent number: 8420069Abstract: A polymeric material, methods of making the polymeric material, articles that include the polymeric material, and compositions that contain the polymeric material are provided. The polymeric material has a plurality of different pendant groups that include a first pendant group containing a —COOH group or a salt thereof, a second pendant group containing a poly(alkylene oxide) group, a third pendant group containing a silicon-containing group, and a fourth pendant group containing a quaternary amino group. The polymeric material can be used, for example, to provide coatings that can be antifouling, antimicrobial, or both.Type: GrantFiled: August 25, 2009Date of Patent: April 16, 2013Assignee: 3M Innovative Properties CompanyInventors: John J. Stofko, Jr., Jeremy M. Yarwood
-
Patent number: 8404793Abstract: It is an object of the present invention to provide an allergen suppressor exerting an effect of suppressing an allergen under humidities normally used, and an allergen-suppression processed fiber, which can suppress an allergen adhering to fibers automatically without applying an allergen-suppression process and a method of producing the same. That is, the present invention is an allergen suppressor, which contains a hydrophilic polymer and a component suppressing an allergen.Type: GrantFiled: January 7, 2004Date of Patent: March 26, 2013Assignee: Sekisui Chemical Co., Ltd.Inventors: Taro Suzuki, Mitsuhito Teramoto, Akihiko Fujiwara
-
Publication number: 20130071482Abstract: A nanoassembly includes a core protected by a biocompatible shell. The nanoassembly includes a plurality of block copolymers including drug-binding linkers and block copolymer cross-linkers. A first active agent is covalently conjugated to the plurality of block copolymers and a second active agent is physically entrapped in the core.Type: ApplicationFiled: September 20, 2012Publication date: March 21, 2013Applicant: THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventor: The University of Kentucky Research Foundation
-
Patent number: 8383093Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.Type: GrantFiled: June 15, 2012Date of Patent: February 26, 2013Assignee: Serina Therapeutics, Inc.Inventors: Randall Moreadith, Michael David Bentley, Kunsang Yoon, Zhihao Fang, Rebecca Weimer, Bekir Dizman, Tacey Viegas
-
Patent number: 8378059Abstract: This invention pertains generally to supramolecular polymers comprising a polymeric molecule linked to a first CB[8] guest molecule and an attachment compound linked to a second CB[8] guest molecule, wherein the first and second CB[8] guest molecules form a ternary host-guest complex with a CB[8] molecule which non-covalently links the polymeric molecule and the attachment compound in a supramolecular polymer. These polymers are useful as vehicles for delivery of a therapeutic compound for use in a method of treatment of the human or animal body, in particular for use in a method of delivering the therapeutic compound to a target site in an individual. The invention also provides methods for the preparation of the supramolecular polymers.Type: GrantFiled: December 4, 2008Date of Patent: February 19, 2013Assignee: Cambridge Enterprise Ltd.Inventors: Urs Rauwald, Oren Alexander Scherman
-
Publication number: 20130039878Abstract: The present invention relates to a method for manufacturing a triple cross-linked collagen, which comprises the following steps: providing a soluble collagen sample; mixing the collagen sample with a first cross-linking agent to form a one cross-linked collagen; mixing the first cross-linked collagen with a second cross-linking agent to form a second cross-linked collagen; and mixing the second cross-linked collagen with a third cross-linking agent to form a triple cross-linked collagen, wherein each of the first cross-linking agent, the second cross-linking agent, and the third cross-linking agent is selected from the group consisting of an aldehyde cross-linking agent, an imine cross-linking agent, and an epoxide cross-linking agent. In addition, the first cross-linking agent is different form the second cross-linking agent, and the third cross-linking agent is different form the first cross-linking agent and the second cross-linking agent.Type: ApplicationFiled: April 10, 2012Publication date: February 14, 2013Applicant: SunMax Biotechnology Co., Ltd.Inventors: Yu-Te LIN, Chien-Hsin Lin, Hsiang-Yin Lu, Feng-Huei Lin
-
Publication number: 20130039954Abstract: Disclosed are synthetic nanocarrier compositions that comprise B cell antigen for desired antibody production and an off-target response attenuating polymeric coating as well as related methods.Type: ApplicationFiled: July 27, 2012Publication date: February 14, 2013Applicant: Selecta Biosciences, Inc.Inventors: Lynnelle Ann McNamee Pittet, David H. Altreuter, Yun Gao, Petr Ilyinskii, William Kuhlman
-
Patent number: 8372422Abstract: Isolatable, hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are provided. The polymeric structure includes a linear or branched water-soluble and non-peptidic polymer backbone, such as a PEG backbone, having at least two termini, a first terminus being covalently bonded to a hydroxyapatite-targeting moiety, such as a bisphosphonate, and a second terminus covalently bonded to a chemically reactive group, wherein said chemically reactive group is protected or unprotected. Methods of preparing and using hydroxyapatite-targeting polymeric structures, and biologically active conjugates thereof, are also provided.Type: GrantFiled: October 6, 2010Date of Patent: February 12, 2013Assignee: Nektar TherapeuticsInventors: Antoni Kozlowski, Michael J. Roberts
-
Publication number: 20130022569Abstract: The invention provides hydrogels comprising bioactive-based poly(anhydride-ester)s (PAEs) and methods for use thereof.Type: ApplicationFiled: May 16, 2012Publication date: January 24, 2013Inventors: Kathryn E. Uhrich, Ashley L. Howell, Renata Fogaça da Silva, Luiz Henrique Catalina, Michelle Aimeé Ouimet
-
Publication number: 20130017166Abstract: The present invention provides polymer conjugates and methods of use thereof.Type: ApplicationFiled: April 7, 2011Publication date: January 17, 2013Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Alexander V. Kabanov, Jing Tong
-
Publication number: 20130011457Abstract: Biodegradable cationic block copolymers are disclosed, comprising a hydrophilic block comprising first repeat units derived from a first cyclic carbonyl monomer by ring-opening polymerization, wherein more than 0% of the first repeat units comprise a side chain moiety comprising a quaternary amine group; a hydrophobic block comprising second repeat units derived from a second cyclic carbonyl monomer by ring-opening polymerization; an optional endcap group; and a chain fragment derived from an initiator for the ring opening polymerization. The cationic block copolymers form aqueous micelle mixtures suitable for antimicrobial applications.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: James Hedrick, Kazuki Fukushima, Yi Yan Yang
-
Patent number: 8349309Abstract: A pharmaceutically-active polymeric compound of the general formula (I), Y-[Yn-LINK B-X]m-LINK B??(I) wherein (i) X is a coupled biological coupling agent of the general formula (II) Bio-LINK A-Bio??(II) wherein Bio is a biologically active agent fragment or precursor thereof linked to LINK A through a hydrolysable covalent bond; and LINK A is a coupled central flexible linear first segment of <2000 theoretical molecular weight linked to each of said Bio fragments; (ii) Y is LINK B-OLIGO; wherein (a) LINK B is a coupled second segment linking one OLIGO to another OLIGO and an OLIGO to X or precursor thereof; and (b) OLIGO is a short length of polymer segment having a molecular weight of less than 5,000 and comprising less than 100 monomeric repeating units; (iii) m is 1-40; and (iv) n is selected from 2-50. The compounds are useful as biomaterials, particularly, providing antibacterial activity in vivo.Type: GrantFiled: June 3, 2010Date of Patent: January 8, 2013Assignee: Interface Biologics Inc.Inventors: J. Paul Santerre, Mei Li
-
Publication number: 20130004453Abstract: Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins Band C (SP-B and SP-C), two helical and amphiphilic proteins that are clitical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restlicted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-R mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, arc prepared by ling-opening polymelization of 13-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.Type: ApplicationFiled: March 17, 2011Publication date: January 3, 2013Inventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
-
Patent number: 8343473Abstract: A bactericidal or antimicrobial polymeric composition includes a hydrophilic first comonomer copolymerized to a second comonomer to produce a polymeric composition that is more hydrophilic or more bactericidal or antimicrobial in an aqueous solution than either of the comonomers alone. Methods for identifying bactericidal or antimicrobial polymers, methods for rendering materials bactericidal or antimicrobial, and methods for using bactericidal or antimicrobial compositions to kill or reduce bacterial or microbial growth are also described. Applications for the inventive compositions include their use in catheters, stents, medical devices, contact lenses; root canal fillers; fibers; paper; and/or wound dressing.Type: GrantFiled: August 27, 2009Date of Patent: January 1, 2013Assignee: Purdue Research FoundationInventors: Jeffrey P. Youngblood, Philippe H. Sellenet, Thomas R. Stratton
-
Patent number: 8338545Abstract: The invention provides methods for making copolymers and multi-arm block copolymers useful as drug delivery vehicles. The multi-arm block copolymers comprise a central core molecule, such as a residue of a polyol, and at least three copolymer arms covalently attached to the central core molecule, each copolymer arm comprising an inner hydrophobic polymer segment covalently attached to the central core molecule and an outer hydrophilic polymer segment covalently attached to the hydrophobic polymer segment, wherein the central core molecule and the hydrophobic polymer segment define a hydrophobic core region. The solubility of hydrophobic biologically active agents can be improved by entrapment within the hydrophobic core region of the block copolymer. The invention further includes pharmaceutical compositions including such block copolymers, pharmaceutical compositions, and methods of using the block copolymers as drug delivery vehicles.Type: GrantFiled: November 2, 2011Date of Patent: December 25, 2012Assignee: Nektar TherapeuticsInventor: Xuan Zhao
-
Patent number: 8323633Abstract: This invention provides a method of inactivating non-enveloped virus particles. The method includes the step of contacting the virus with a virucidally-enhanced alcoholic composition that includes an alcohol, and an enhancer selected from the group consisting of cationic oligomers and polymers, proton donors, chaotropic agents, and mixtures thereof.Type: GrantFiled: February 6, 2012Date of Patent: December 4, 2012Assignee: GOJO Industries, Inc.Inventors: Marcia Snyder, David R. Macinga, James W. Arbogast
-
Publication number: 20120251592Abstract: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner to form a flexible tether and/or entrap the peptide. The entrapped peptide provides antimicrobial action by early release from entrapment while the tethered peptide provides longer lasting antimicrobial protection. Antimicrobial gels and foams may be prepared using the antimicrobial peptide containing block copolymers.Type: ApplicationFiled: May 15, 2012Publication date: October 4, 2012Applicants: The State of Oregon Acting by & through the State Board of Higher Ed. on Behalf of Oregon State Univ, ALLVIVO VASCULAR, INC.Inventors: Jennifer A. Neff, Joseph McGuire, Pranav R. Joshi
-
Publication number: 20120230937Abstract: The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2?CR1)CO—K (I) wherein: K represents 0-Z or NH—Z, Z representing (CR2R3)m—CH3, (CH2—CH2—O)m—H, (CH2—CH2—O)m—CH3, (CH2)m—NR4R5 with m representing an integer from 1 to 30; R1, R2, R3, R4 and R5 independently represent H or a C1-C6 alkyl; and (ii) at least one bio-resorbable block copolymer cross-linker.Type: ApplicationFiled: September 9, 2010Publication date: September 13, 2012Applicants: OCCLUGEL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS DIDEROT PARIS 7, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, UNIVERSITE PARIS-SUD 11Inventors: Laurence Moine, Laurent Bedouet, Alexandre Laurent, Denis Labarre, Michel Wassef, Van Nga Nguyen
-
Publication number: 20120231044Abstract: A vaccine formulation as disclosed which is comprised of a pharmaceutically acceptable carrier in a plurality of particles with mannose on their surface. The particles are comprised of a biocompatible polymer which maybe a co-polymer such as PLGA combined with a peptide of a sequence which corresponds to a sequence on a surface of a pathogen. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than a single particle from being presented to a single immune system cell.Type: ApplicationFiled: March 12, 2012Publication date: September 13, 2012Inventors: Charles Vincent Taylor Herst, Reid M. Rubsamen
-
Publication number: 20120231060Abstract: A covalently crosslinked hydrogel comprises a) three or more divalent poly(alkylene oxide) chains P? covalently linked at respective first end units to a branched first core group C?, b) three or more divalent poly(alkylene oxide) chains P? covalently linked at respective first end units to a branched second core group C?, the chains P? comprising respective second end units which are covalently linked to between 0% and 100% of respective second end units of chains P? by divalent linking groups L?, and c) at least one pendant cationic block copolymer chain A?-B?. A?-B? comprises i) a divalent block A? comprising a poly(alkylene oxide) backbone chain having an end unit covalently linked to a second end unit of one of the chains P? by a divalent linking group L?, and ii) a monovalent block B? comprising a first repeat unit, the first repeat unit comprising a backbone carbonate group and a cationic side chain group.Type: ApplicationFiled: August 19, 2011Publication date: September 13, 2012Applicants: INTERNATIONAL BUSINESS MACHINES CORPORATIONInventors: Daniel Joseph Coady, Amanda Catherine Engler, James Lupton Hedrick, Shaoqiong Liu, Yi Yan Yang, Chuan Yang
-
Patent number: 8252276Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: GrantFiled: March 15, 2012Date of Patent: August 28, 2012Assignee: Cerulean Pharma Inc.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Publication number: 20120207700Abstract: This present invention relates generally to the use of novel formulations comprising a surface active polymer to enhance oxygenation in skin and other soft tissue. The present invention also discloses formulations that can be used to improve clinical outlook and reducing bacteria. Methods of making and using the same are also disclosed.Type: ApplicationFiled: May 19, 2010Publication date: August 16, 2012Inventors: Neal Koller, George Rodeheaver, Roberto Cassino
-
Publication number: 20120171152Abstract: Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided.Type: ApplicationFiled: March 9, 2012Publication date: July 5, 2012Inventors: Alexander V. Kabanov, Xiang Yi, Sarguel V. Vinogradov, William A. Banks